Showing results (81-90 of 90) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 90 results.
Cell Discovery|October 17, 2023
Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosisZhaoxian Cai, Xiaotian Wu, Zijun Song, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFRJianwei Wu, Wenteng Chen, Guangxin Xia, et al.
Journal of Medicinal Chemistry|March 27, 2020
CN128: A New Orally Active Hydroxypyridinone Iron ChelatorWenteng Chen, Xin Yuan, Zhi Li, et al.
Frontiers of Medicine|May 2, 2023
ACSL5, a prognostic factor in acute myeloid leukemia, modulates the activity of Wnt/β-catenin signaling by palmitoylation modificationWenle Ye, Jinghan Wang, Jiansong Huang, et al.
Ebiomedicine|November 26, 2018
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effectsXia Li, Chenying Li, Jingrui Jin, et al.
Nature Communications|March 13, 2026
Catalytic Proximal Protein Oligomerization as an Anti-Tumor Strategy Targeting WDR5Yizheng Fang, Li Jiang, Feifan Wang, et al.
Cell Metabolism|August 14, 2024
Integrative clinical and preclinical studies identify FerroTerminator1 as a potent therapeutic drug for MASHLiang Tao, Xinquan Yang, Chaodong Ge, et al.
Journal of Medicinal Chemistry|November 20, 2014
A chemical tuned strategy to develop novel irreversible EGFR-TK inhibitors with improved safety and pharmacokinetic profilesGuangxin Xia, Wenteng Chen, Jing Zhang, et al.
European Journal of Medicinal Chemistry|March 15, 2025
Naturally inspired chimeric quinolone derivatives to reverse bacterial drug resistanceQi Wen, Yuhang He, Jiaying Chi, et al.
European Journal of Medicinal Chemistry|January 7, 2015
Synthesis and biological evaluations of novel endomorphin analogues containing α-hydroxy-β-phenylalanine (AHPBA) displaying mixed μ/δ opioid receptor agonist and δ opioid receptor antagonist activitiesMiao Hu, Marc A Giulianotti, Jay P McLaughlin, et al.
Pageof 9